Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

Eli Lilly’s Taltz shows superiority over AbbVie’s Humira

December 18, 2018
Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …

News
lilly_entrance_web

Eli Lilly’s Emgality cleared for treatment of migraine in Europe

November 20, 2018
Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma

Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …

News
lilly_building_with_american_flag_web

Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

November 7, 2018
Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …

News
shutterstock_360472550

Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis

October 24, 2018
Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma

Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …

News

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …

News
lilly_entrance_web

NICE rejects Elil Lilly’s Verzenio for breast cancer in draft guidance

October 19, 2018
Medical Communications, Sales and Marketing Eli Lilly, NICE, UK, Verzenios, breast cancer, pharma

Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that …

News

Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer

October 3, 2018
Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …

News

NICE recommends Eli Lilly’s psoriatic arthritis drug

August 9, 2018
Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …

News
lilly_entrance_web

Eli Lilly’s dulaglutide doses show blood control and weight benefits at Phase 2

June 25, 2018
Research and Development, Sales and Marketing Eli Lilly, Trulicity, diabetes, pharma

Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg …

News
nerve-cell-2213009_960_720

Another failure in Alzheimer’s creates bleak outlook for treatment

June 12, 2018
Manufacturing and Production, Research and Development Alzheimer's, AstraZeneca, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …

News

Eli Lilly’s President of Oncology to retire

June 5, 2018
Research and Development Cancer, Eli Lilly, appointment, oncology, pharma

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …

News
lilly_building_with_american_flag_web

FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats

June 5, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma

Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …

News
lilly_entrance_web

Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form

May 16, 2018
Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma

Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …

News
lilly_building_with_american_flag_web

Lilly chalks up another acquisition with AurKa for $575m

May 14, 2018
Manufacturing and Production, Sales and Marketing AurKa, Cancer, Eli Lilly, acquisition, oncology, pharma

Swiftly following up its $1.6 billion splash to pick up Armo BioSciences last week, Eli Lilly has agreed to acquire …

News
lilly2_web

Lilly moves quickly to secure $1.6bn buyout of Armo

May 10, 2018
Medical Communications, Sales and Marketing Armo Biosciences, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Armo BioSciences only went public in January but it has already been snapped up by Eli Lilly for $1.6 billion. …

News

Latest content

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024

Innate Pharma shares results from phase 1/2 trial for blood cancer treatment

June 17, 2024

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024